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tumor) of facial bones: a case report and review
of literature
Bin LI1, Yang Li1, Xiao-ying Tian2 and Zhi Li1*Abstract
Papillary intralymphatic angioendothelioma (PILA) or Dabska tumor is extremely rare, and often affects the skin and
subcutaneous tissues of children. Since its first description by Dabska, only a few intraosseous cases have been described
in the literature and none of them presents with multifocal osteolytic lesion of bones. We present a case of unusual
multifocal intraosseous PILA in facial bones occurring in a 1 year 3 month old male child. Computed tomography (CT)
scan revealed multifocal osteolytic lesions were located at the left zygoma, left orbital bone and right maxillary.
Histologically, the lesions were ill-defined and composed of multiple delicate interconnecting vascular channels with
papillae formation which projected into the lumen lined by atypical plumped endothelial cells. The vascular channels
were also lined by plump cuboidal endothelial cells with focal hobnailed or “match-head” appearance. In some areas,
endothelial cells formed solid-appearing aggregates with vessel lumens. By immunohistochemistry, the tumor cells were
positive for CD31, CD34 and D2-40 at varying intensity. A final diagnosis of intraosseous PILA was made. To the best of
our knowledge, this case is the first case of primary multifocal osseous PILA.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1919488629100787
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Papillary intralymphatic angioendothelioma (PILA) or
Dabska tumor is a locally aggressive, rarely metastasizing
vascular lesion characterized by lymphatic- or vascular-
like channels and papillary endothelial proliferation.
The tumor is extremely rare, and often affects the skin
and subcutaneous tissues of children [1]. Since its first
description in 1969 by Dabska et al. only 33 cases have
been described in the literature [2-13]. PILA does not
appear to have any particular predilection site, but
many of the reports were in dermis and subcutaneous
tissues of head, neck, and extremities. Only a few cases of
this tumor have also been described in deeper locations,
including spleen, tongue, testis, and bone [8,10,11,13,18].* Correspondence: lizhi@mail.sysu.edu.cn
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reproduction in any medium, provided the orSo far, only two cases of intraosseous PILA have been de-
scribed in the literature, with none of these cases originat-
ing from facial bone. Herein, we present first case of
multifocal PILA arising in facial bones of a 1-year old boy.
The clinical and histological features of this tumor, as well
as differential diagnosis are discussed.Case presentation
Clinical presentation and management
A 1 year 3 month old Chinese male child was referred
to our pediatric department for pain and swelling on his
left side of face for past 2 weeks. In the past two weeks,
the baby was suffering from a gradually severe soft tissues
swelling on his left face. Two days before admission to our
hospital, the pain and tenderness of left face became
worse. As a result, the patient was referred to our hospital
for examination and treatment. There was no history of
any trauma to head and neck. Physical examinationhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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his left upper face and severe pain was elicited upon
pressure. There was no fever, weight loss and no palpable
lymphadenopathy or organomegaly. The laboratory re-
sults, including blood count, differential, liver and renal
function, were within the normal range. A computed
tomography (CT) scan of the head revealed multifocal
osteolytic lesions in the facial bones, including left
zygomatic bone (measuring 1.5 × 1.0 × 1.0 cm in size),
left orbital bone (measuring 0.5 cm in diameter) and
right maxillary bone (measuring 1.0 cm in diameter).
The most of left zygoma was observed to be destroyed
and associated soft tissue mass was also noted (Figure 1).
The lesions showed moderate enhancement after meg-
lumine diatrizoate injection. There was no enlarged lymph
node found in head and neck. A CT scan of neck and
abdomen showed no pathologic findings, particularly
no lymphadenopathy could be observed. A CT guided
needle biopsy was performed on left zygomatic bone
initially, but histopathological examination showed piecesFigure 1 Radiographic examination of the lesions. (A) Cmputed tomog
(white arrow). (B) A osteolytic lesion of the left zygomatic bone (white arro
scan showed multiple osseous destruction of maxillary bone (black arrow)
in soft tissue windows revealed that an irregular mass destroyed the left zyof fibrosis with infiltration of inflammatory cells. From
the clinical and radiographic evaluations, the lesion was
preoperatively diagnosed as Langerhans cell histiocytosis
(eosinophilic granuloma) of bone. The patient underwent
curettage of the zygomatic and maxillary lesions. Because
the margin of the lesions was ill-defined, the curettage was
extensive. The postoperative phase was uneventful, and no
additional treatments were undertaken. The pain resolved
postoperatively and the patient was on regular follow-up
for 24 months after discharging from hospital. A follow-up
CT scan at 6 months after surgery revealed unchanged
lesion of left orbital bone and there was no sign of re-
currence of tumor and lymph node enlargement.
Histopathological findings
The surgical samples were routinely fixed in 10% neutral
buffered formalin. The tissues were embedded in paraffin.
Four micrometer-thick sections were stained with H&E.
Immunohistochemical analyses were performed using the
ChemMate Envision/HRP Kit (Dako, Glostrup, Denmark).raphy (CT) scan showed osteolytic lesions of the left orbital bone
w) appeared to have an indistinct border in periphery. (C) Coronal CT
and left zygomatic bone (white arrow). (D) Postcontrast axial CT scan
gomatic bone (white arrow).
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of antibodies against cytokeratin (AE1/AE3), epithelial
membrane antigen (EMA), vimentin, desmin, smooth
muscle actin (SMA), CD31, CD34, D2-40, CD1a, CD68,
S100 protein, Langerin, and Ki-67. The antibodies were
obtained from Dako Cytomation (Glostrup, Denmark)
and Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Under microscopic examination, both zygomatic and
maxillary lesion showed an ill-defined neoplasm within
the osseous fragments. The lesions were composed of
multiple delicate interconnecting vascular channels
with papillae formation which projected into the lumen
lined by atypical plumped endothelial cells. Some of
those papillae contained hyalinized core. The vascular
channels were also lined by plump cuboidal endothelial
cells with focal hobnailed or “match-head” appearance.
In some areas, endothelial cells formed solid-appearing
aggregates with vessel lumens. A variable number of lym-
phocytes are seen within and around the vascular chan-
nels. Mitotic figures were rare and necrosis was not
observed in the lesions (Figure 2A-C).
Immunohistochemical findings
Immunohistochemistry stains done on these lesions were
positivity for CD34 and CD31. Staining for CD31 was
stronger than that for CD34. Endothelial cells of lumens
expressed CD31, CD34 and D2-40, but the intraluminal
tumor cells were negative for D2-40 (F). These lesions did
not express CD1a, S-100 protein, cytokeratin (AE1/AE3),
EMA, langerin, CD68 and SMA. The Ki-67 labeling index
of the lesions was low, accounting for 2% of the tumor
(Figure 2D-F). Based on the pathological findings, the
mutifocal intraosseous lesions of facial bones were di-
agnosed as papillary intralymphatic angioendothelioma
(PILA) according to WHO diagnostic criteria [1].
Discussion
Papillary intralymphatic angioendothelioma (PILA), ori-
ginally termed as endovascular papillary angioendo-
thelioma (EPA), or Dabska tumor, was first presented
in 1969 by Maria Dabska where she presented cases oc-
curring in 6 children. In her originally reported cases,
EPA was regarded as malignant and termed “malignant
endovascular papillary angioendothelioma” because two
of six patients had lymph node metastases [14]. Since
then, a few reports of similar cases were published,
often called “Dabska tumors.” In 1999, Fanburg-Smith
JC and his colleagues described 12 similar cases and
designated those tumors as “papillary intralymphatic
angioendothelioma (PILA)” because of histologic and
immunophenotypic evidence of lymphatic vessels [12].
Moreover, a growing number of cases described in the
literature and the accumulating knowledge reveal that
presence of highly specific lymphatic endothelial markerD2-40 and tumor marker vascular endothelial cell growth
factor receptor type 3 (VEGFR 3) suggest tumor’s lymph-
atic origin other than hemangioma [15,16]. In 2002,
World Health Organization (WHO) classification of
tumors of soft tissue and bone accepted PILA as a rare
entity, and identified it as a locally aggressive, rarely
metastasizing “vascular lesion characterized by lymphatic-
like channels and papillary endothelial proliferation” [17].
In 2013, the latest edition of WHO tumor classification
(4th edition) revised tumor description to “rarely metasta-
sizing lymphatic vascular neoplasm”, which further sup-
ports lymphatic origin or differentiation of this tumor [1].
Since its first description by Dabska et al. only ap-
proximately 33, predominantly pediatric cases have been
described in the literature. Of these 19 were children
and 14 were adults without sex predilection. It appears
that PILA may affect a wider age range than originally
described by Dabska. The age range for all reported
cases is from birth to 83 years. PILA does not show a
preference for a specific anatomic site, but most of
tumors involve the dermis and subcutaneous tissues of
extremities (especially thigh and buttocks). The tumor
has also been described in other deeper locations,
including spleen [18], tongue [11], testis [8] and bone
[10,13]. Intraosseous PILA confined to the bone is quite
rare that only 2 cases have been reported worldwide to
date. McCarthy et al. reported the first cases of Dabska
tumor in the distal femur of a 45-year-old woman [13].
Also, Nakayama and his colleagues reported a lesion in
the medial distal metaphysis of the femur in a 39-year-old
woman [10]. In those cases, a single intraosseous lesion
was observed in the involved bone (Table 1). However,
there have been no reported cases of this lesion occurring
in several facial bones with multiple foci. To the best of
our knowledge, our case is the first case of primary
multifocal osseous PILA. Clinically, PILA presents as a
slowly growing asymptomatic cutaneous or soft tissue
nodule, it usually comes to medical attention when
significantly bigger in size (approximately 2–3 cm in
diameter). Cases of reported PILA have ranged in size
from 1 to 40 cm [12]. In the present case, pain and soft
tissues swelling is the primary clinical manifestation
instead of a palpable nodular lesion.
Since cases of intraosseous PILA are so rare, the diagno-
sis should be only made by strict histological and clinical
manifestation. According to the WHO criteria, PILA ap-
pears similar to cavernous lymphangiomas. The cuboidal
or hobnail endothelial cells lining the vascular structures
are characterized by a high nuclear cytoplasmic ratio
and an apically placed nucleus that produces a surface
bulge, accounting for the term "hobnail" or "matchstick".
Immunohistochemically, vascular endothelial markers
such as Von-Willebrand factor, CD34, CD31 and Fli-1 are
commonly positive in most of tumors at varying intensities
Figure 2 Photomicrographs of the osseous lesions. (A) Microscopic examination demonstrated ill-defined neoplasm composed of vascular
lumen and endothelial cell proliferation forming glomerulus-like structures. (B) Delicate papillaries consisted of hyaline cores lined by prominent
atypical nucleus and inconspicuous cytoplasm. (C) High-power photomicrograph demonstrated the characteristic “hobnail” appearance of the
prominent endothelial cells. (D) Immunohistochemical staining showed the tumor cells strongly positive for CD31, but less positive for CD34 (E).
Endothelial cells of lumens expressed D2-40, but the intraluminal tumor cells were negative for D2-40. (A, HE staining with original magnification ×
100; B, HE staining with original magnification × 200; C, HE staining with original magnification × 400; D-F, immunohistochemical staining with original
magnification × 200).
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as a type of vascular neoplasms. Of these markers, CD31
has been the best marker for this tumor because of its high
sensitivity and specificity for vascular endothelial cells.
CD31 usually has more immunohistochemical intensity
than CD34 [12]. Moreover, the presence of podoplanin
(D2-40) and vascular endothelial growth factor receptor-3
(VEGFR3) have been also confirmed by immunohis-
tochemical staining, which are highly specific lymphatic
endothelial markers and suggest that the tumor is more
similar to a tumor of lymphatic origin [12,15]. However,the absence of D2-40 and CD34 in tumor cells could also
be found in several previously reported cases [4]. In the
present case, irregular vascular channels lined by endothe-
lial cells with a “hobnail” appearance, papillary projections
with a central hyaline core and scarce mitotic figures help
identify the tumor as a “hobnail” hemangioendothelioma.
The immuno-positivity of D2-40 points to a lymphatic ori-
gin of this tumor.
Intraosseous PILA usually show osteolysis in radio-
logical examination (especially multifocal osteolytic le-
sions of bones in our current case), it is often misdiagnosed
Table 1 Clinicopathological features of intraosseous PILAs described in present and previous reports
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EPA, endovascular papillary angioendothelioma; PILA, papillary intralymphatic angioendothelioma; NED, no evidence of disease; +, positive.
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http://www.diagnosticpathology.org/content/8/1/160as eosinophilic granuloma of bone preoperatively. How-
ever, eosinophilic granuloma of bone shows clonal neo-
plastic proliferation of Langerhans cells that express
CD1a, S-100 and Langerin. The absence of those specific
Langerhans cell markers will rule out the diagnosis of eo-
sinophilic granuloma. Importantly, two particular types of
vascular lesions, retiform hemangioendothelioma and
papillary endothelial hyperplasia (Masson's lesion),
may also be confused with the PILA, because of pres-
ence of “hobnail” cells or irregular papillary projections
in vascular channels. Retiform hemangioendothelioma
is a locally aggressive vascular tumor and characterized
by distinctive arborizing blood vessels lined by endo-
thelial cell with “hobnail” morphology. The elongated,
branched vessels impart a pattern reminiscent of rete
testis. That histological appearance is not consistent to
the PILA. Papillary endothelial hyperplasia, also known
as Masson's lesion, is a reactive endothelial prolifera-
tion secondary to vascular thrombosis. The lesion
shows branching papillary projections, many of which
are free-floating in the vascular lumens. Thrombotic
material is usually present in the vascular lumens. More-
over, these histologically similar vascular lesions do not
express D2-40 and VEGFR3, which are specific markers
for PILA. In addition, epithelioid hemangioendothelioma
of bone has recently been reported in literature [19], and
lymphangioma-like Kaposi sarcoma may infrequently be
encountered in clinical practice [20]. These tumors might
be confused with PILA because of endothelial cells prolif-
eration and vascular structure with immunopositivity of
vascular markers. However, presences of “hobnail” cells
and papillary projections in vascular channels support the
diagnosis of PILA.
Although PILA was identified initially as a “low-grade
angiosarcoma”, following-up in more recent series dem-
onstrated no local recurrence or metastasis [12]. Most of
cases have excellent prognosis with complete, wide exci-
sion [13]. But high-grade angiosarcoma arising within a
Dabska tumor suggests the tumor’s malignant potentialin individual case [6]. Dabska performed a 30-year re-
view of this tumor and the outcomes of the 6 patients
she presented in 1969. Three of the original 6 cases
were locally aggressive, with tumor invasion into
deeper structures. Only one patient ultimately died of
widespread pulmonary metastases [21]. However, Up to
now, no other articles have been written describing the
malignant metastatic potential of the tumor, although
the tumor has been described to occur in lymph node
[4]. In the present case there was no evidence of any
nodal involvement or distant metastasis and the child
was doing well on last follow up after 24 months of sur-
gery. However, PILA can be locally invasive with a po-
tential to metastasize, a long-term follow-up should be
performed to supervise the locoregional recurrence.
Conclusion
Because of its rarity and histological complexity, there
exist diagnostic challenges for pathologists to differenti-
ate PILA from other benign, intermediate or malignant
vascular lesions. It is important to be able recognize this
tumor in order to avoid potential misdiagnosis and im-
proper management of afflicted patients. Our additive
case is also presented for its rarity of site. It is the first
case of intraosseous PILA with multiple lesions of facial
bones. The diagnosis of intraosseous PILA is difficult
and should be made cautiously. Besides confirmation by
strict morphological criteria, immunohistochemical ana-
lysis is helpful for demonstrating the lymphatic pheno-
type of tumor.
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